XNAS · Healthcare · Biotechnology
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.14 | -0.03 | +78.57% | $305.1M | ✅ Beat | +1.64% | -4.67% | — |
| 2026-03-10 | Q4 2025 | -0.18 | 0.01 | +105.56% | $306.3M | ✅ Beat | +2.35% | -5.16% | -6.95% |
| 2025-11-12 |
| Q3 2025 |
| -0.12 |
| -0.05 |
| +58.33% |
| $272.3M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.21 | -0.34 | -61.90% | $255.1M | ❌ Miss | +0.14% | +3.34% | -7.64% |
| 2025-03-11 | Q4 2024 | -0.33 | -0.15 | +54.55% | $186.5M | ✅ Beat | +2.82% | +1.86% | -15.89% |
| 2024-08-09 | Q2 2024 | -0.38 | -0.05 | +86.84% | $186.5M | ✅ Beat | +0.63% | +1.77% | -9.91% |
| 2024-05-13 | Q1 2024 | -0.34 | -0.16 | +52.94% | $94.0M | ✅ Beat | +3.28% | +5.72% | +6.47% |
| 2024-03-11 | Q4 2023 | -0.83 | -0.40 | +51.81% | $79.5M | ✅ Beat | — | — | — |
Showing last 8 quarters.